EF Hutton Assumes Coeptis Therapeutics at Buy, Maintains Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Michael King assumes Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and maintains a price target of $10.
May 25, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coeptis Therapeutics receives a Buy rating from EF Hutton analyst Michael King, with a maintained price target of $10.
The Buy rating from EF Hutton analyst Michael King indicates a positive outlook for Coeptis Therapeutics. The maintained price target of $10 suggests that the stock has potential for growth in the short term. This news is highly relevant and important for investors in COEP, as analyst ratings can influence market sentiment and stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100